Clinical Research Directory
Browse clinical research sites, groups, and studies.
Registry of Patients Having Received oNKord®
Sponsor: Glycostem Therapeutics BV
Summary
ReKORD is an observational study (Registry) enrolling participants who have received at least one dose of oNKord® (allogeneic ex vivo-generated Natural Killer \[NK\] cells from CD34+ umbilical cord blood progenitor cells) in a clinical trial. Participants from multiple previous clinical trials of oNKord® can be enrolled in this Registry.
Official title: A Prospective Multicenter Observational Study to Assess Long-term Outcome of Participants Who Have Received oNKord®
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
50
Start Date
2022-06-14
Completion Date
2028-03
Last Updated
2022-08-04
Healthy Volunteers
Not specified
Conditions
Interventions
oNKord®
Allogeneic ex vivo-generated Natural Killer (NK) cells from CD34+ umbilical cord blood progenitor cells
Cyclophosphamide/Fludarabine (Cy/Flu)
Lymphodepleting conditioning regimen
Locations (2)
Medizinische Hochschule Hannover
Hanover, Germany
University Hospital Basel
Basel, Switzerland